Free Trial
NYSE:INFU

InfuSystem (INFU) Stock Price, News & Analysis

InfuSystem logo
$8.97 +0.04 (+0.45%)
(As of 05:20 PM ET)

About InfuSystem Stock (NYSE:INFU)

Key Stats

Today's Range
$8.87
$9.16
50-Day Range
$5.84
$9.51
52-Week Range
$5.74
$10.99
Volume
93,886 shs
Average Volume
59,495 shs
Market Capitalization
$190.70 million
P/E Ratio
149.52
Dividend Yield
N/A
Price Target
$13.00
Consensus Rating
Strong Buy

Company Overview

InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.

InfuSystem Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
47th Percentile Overall Score

INFU MarketRank™: 

InfuSystem scored higher than 47% of companies evaluated by MarketBeat, and ranked 662nd out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for InfuSystem are expected to grow by 106.67% in the coming year, from $0.15 to $0.31 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of InfuSystem is 149.52, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 136.02.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of InfuSystem is 149.52, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 131.84.

  • Price to Book Value per Share Ratio

    InfuSystem has a P/B Ratio of 3.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for INFU.
  • Dividend Yield

    InfuSystem does not currently pay a dividend.

  • Dividend Growth

    InfuSystem does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for INFU.
  • News Sentiment

    InfuSystem has a news sentiment score of 0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 11 news articles for InfuSystem this week, compared to 1 article on an average week.
  • Search Interest

    Only 1 people have searched for INFU on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • MarketBeat Follows

    Only 4 people have added InfuSystem to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, InfuSystem insiders have bought more of their company's stock than they have sold. Specifically, they have bought $23,560.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    10.20% of the stock of InfuSystem is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    71.13% of the stock of InfuSystem is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about InfuSystem's insider trading history.
Receive INFU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InfuSystem and its competitors with MarketBeat's FREE daily newsletter.

INFU Stock News Headlines

B. Riley Issues Pessimistic Estimate for InfuSystem Earnings
War on Elon Escalates…
A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.
Q3 2024 InfuSystem Holdings Inc Earnings Call
Craig-Hallum Sticks to Their Buy Rating for Lifecore Biomedical (LFCR)
InfuSystem Reports Third Quarter 2024 Financial Results
Inotiv (NOTV) Receives a Buy from Craig-Hallum
See More Headlines

INFU Stock Analysis - Frequently Asked Questions

InfuSystem's stock was trading at $7.14 at the start of the year. Since then, INFU shares have increased by 25.6% and is now trading at $8.97.
View the best growth stocks for 2024 here
.

InfuSystem Holdings, Inc. (NYSE:INFU) posted its quarterly earnings results on Thursday, August, 8th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.04 by $0.01. The company had revenue of $33.70 million for the quarter. InfuSystem had a trailing twelve-month return on equity of 2.78% and a net margin of 1.12%.

Top institutional investors of InfuSystem include Greenwood Capital Associates LLC (0.56%), GSA Capital Partners LLP (0.31%), Oppenheimer Asset Management Inc. (0.16%) and Connor Clark & Lunn Investment Management Ltd. (0.06%). Insiders that own company stock include Richard Dilorio, Christopher R Sansone, Carrie Lachance, Barry G Steele, Paul Andrew Gendron, R Rimmy Malhotra, Thomas Mark Ruiz, Addam Chupa, Ralph F Boyd Jr, Kevin Whitman, Kenneth D Eichenbaum, Gregg Owen Lehman and Jeannine Sheehan.
View institutional ownership trends
.

Shares of INFU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that InfuSystem investors own include Advanced Micro Devices (AMD), Tesla (TSLA), NVIDIA (NVDA), Meta Platforms (META), Home Depot (HD), JPMorgan Chase & Co. (JPM) and Netflix (NFLX).

Company Calendar

Last Earnings
8/08/2024
Today
11/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Employees
499
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$13.00
High Stock Price Target
$13.00
Low Stock Price Target
$13.00
Potential Upside/Downside
+43.2%
Consensus Rating
Strong Buy
Rating Score (0-4)
4.00
Research Coverage
2 Analysts

Profitability

Net Income
$870,000.00
Pretax Margin
2.65%

Debt

Sales & Book Value

Annual Sales
$125.79 million
Cash Flow
$0.61 per share
Book Value
$2.61 per share

Miscellaneous

Free Float
19,095,000
Market Cap
$193.04 million
Optionable
Optionable
Beta
1.45
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

This page (NYSE:INFU) was last updated on 11/14/2024 by MarketBeat.com Staff
From Our Partners